These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Abnormalities of cell-mediated immunocompetence in genitourinary cancer. Catalona WJ; Chretien PB; Trahan EE J Urol; 1974 Feb; 111(2):229-32. PubMed ID: 4855735 [No Abstract] [Full Text] [Related]
4. Prognostic value of host immunocompetence in urologic cancer patients. Catalona WJ; Smolev JK; Harty JI J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475 [TBL] [Abstract][Full Text] [Related]
5. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer. Elhilali MM; Brosman SA; Vescera C; Paul JG; Fahey JL Cancer; 1978 May; 41(5):1765-70. PubMed ID: 647626 [No Abstract] [Full Text] [Related]
6. Immunobiology of genitourinary tumors. Lange PH; Hakala TR; Fraley EE Urology; 1973 Nov; 2(5):485-92. PubMed ID: 4358375 [No Abstract] [Full Text] [Related]
7. [Value of DNFB skin testing in patients with bladder cancer (author's transl)]. Hudemann B; Seyfarth M Arch Geschwulstforsch; 1980; 50(2):173-7. PubMed ID: 7436702 [TBL] [Abstract][Full Text] [Related]
8. Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms. Schellhammer PF; Bracken RB; Bean MA; Pinsky CM; Whitmore WF Cancer; 1976 Jul; 38(1):149-56. PubMed ID: 947511 [TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation in patients with urological cancers. Martinez-Piñeiro JA; Muntanola P; Hidalgo L Eur Urol; 1977; 3(3):159-62. PubMed ID: 560302 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers. Duclos H; Schwarzenberg L; Duclos SH; Hugues H; Kuss R Biomedicine; 1977 Jan; 27(1):43-7. PubMed ID: 856314 [TBL] [Abstract][Full Text] [Related]
11. The cancer associated antigen test as an index to failure of complete removal of urological cancers. Wechsler M; Gerfo PL; Feminella J; Lattimer JK J Urol; 1973 Apr; 109(4):699-701. PubMed ID: 4735168 [No Abstract] [Full Text] [Related]
12. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract. Frick J; Aulitzky W; Fuchs D; Hausen A; Joos H; Reibnegger G; Wachter H Urol Int; 1985; 40(3):155-9. PubMed ID: 3874460 [TBL] [Abstract][Full Text] [Related]
13. Immunologic features of genitourinary cancer. Javadpour N Urology; 1973 Aug; 2(2):103-8. PubMed ID: 4129366 [No Abstract] [Full Text] [Related]
14. Immunology of genitourinary tumors. Guinan P; Sadoughi N; Bush IM; John T; Eghrari F; Ablin RJ Urology; 1973 Nov; 2(5):493-9. PubMed ID: 4131868 [No Abstract] [Full Text] [Related]
15. Preliminary report of an immunological study in urological cancer. Serrallach N; Jimenez JF; Aguiló F; Anguera A; Clavo M; Orejas V; Torner V; Serrate R Eur Urol; 1975; 1(2):99-100. PubMed ID: 1241896 [TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen in patients with tumors of the urogenital tract. Reynoso G; Chu TM; Guinan P; Murphy GP Cancer; 1972 Jul; 30(1):1-4. PubMed ID: 5064805 [No Abstract] [Full Text] [Related]
17. [Value of carcinoembryonic antigen (CEA) in the diagnosis of malignant tumors of the urogenital tract]. Rost A; Kneppenberg U; Rost P Helv Chir Acta; 1976 Jul; 43(3):271-8. PubMed ID: 947865 [TBL] [Abstract][Full Text] [Related]